Comparing EnteroMedics (RSLS) and Its Rivals
EnteroMedics (NASDAQ: RSLS) is one of 76 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare EnteroMedics to similar businesses based on the strength of its valuation, profitability, institutional ownership, risk, earnings, analyst recommendations and dividends.
This is a breakdown of current ratings for EnteroMedics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EnteroMedics presently has a consensus price target of $11.03, indicating a potential upside of 598.10%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 10.16%. Given EnteroMedics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe EnteroMedics is more favorable than its rivals.
Volatility and Risk
EnteroMedics has a beta of 3.09, suggesting that its share price is 209% more volatile than the S&P 500. Comparatively, EnteroMedics’ rivals have a beta of 1.25, suggesting that their average share price is 25% more volatile than the S&P 500.
This table compares EnteroMedics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
0.6% of EnteroMedics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 32.5% of EnteroMedics shares are owned by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares EnteroMedics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|EnteroMedics Competitors||$2.14 billion||$229.91 million||-28.36|
EnteroMedics’ rivals have higher revenue and earnings than EnteroMedics. EnteroMedics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
EnteroMedics rivals beat EnteroMedics on 7 of the 12 factors compared.
EnteroMedics Company Profile
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.